CV · CapsoVision, Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company raised approximately $14 million in gross proceeds resulting from the Private Placement described in Note 1. DESCRIPTION OF BUSINESS AND ORGANIZATIONAL STRUCTURE and further discussed in Note 9. COMMON STOCK, it is not probable that these funds are sufficient to fund expenditures necessary to achieve sales growth and innovation objectives. The Company intends to consummate additional capital raising activities, but there is no certainty as to such capital raising activities occurring at all, or occurring with sufficient timing or magnitude, sufficient to alleviate such substantial doubt.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| $13.89M | $13.55M | $11.76M | |
| $6.82M | $6.38M | $5.38M | |
| $7.07M | $7.17M | $6.38M | |
| — | 52.92% | 54.24% | |
| $21.56M | $18.31M | $15.12M | |
| $7.75M | $7.53M | $6.97M | |
| $7.92M | $6.85M | $4.21M | |
| $223K | $216K | $206K | |
| $37.22M | $32.69M | $26.29M | |
| -$30.16M | -$25.52M | -$19.92M | |
| — | -188.25% | -169.42% | |
| -$29.93M | -$25.3M | -$19.71M | |
| $351K | $225K | $30K | |
| -$29.81M | -$25.29M | -$19.89M | |
| $24K | $24K | $11K | |
| -$29.83M | -$25.32M | -$19.9M | |
| — | -186.77% | -169.26% | |
| USD/shares | $3.18 | -$1.03 | -$9.85 |
| USD/shares | $3.18 | -$1.03 | -$9.85 |
| shares | — | 24.56M | 2.02M |
| shares | — | 24.56M | 2.02M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 82 similar-size Medical Devices companies (of 150 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| United States | $10,657,000 | $9,082,000 |
| Non Us | $2,897,000 | $2,674,000 |
| France | $1,248,000 | $1,160,000 |
| Germany | $598,000 | $565,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Product | $14,484,000 | $12,701,000 |
| Service | $916,000 | $780,000 |